# A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)

> **NCT05471856** · PHASE1 · RECRUITING · sponsor: **Boehringer Ingelheim** · enrollment: 66 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** BI 1703880
- **DRUG:** Ezabenlimab

## Key facts

- **NCT ID:** NCT05471856
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-02-24
- **Primary completion:** 2028-09-13
- **Final completion:** 2028-09-13
- **Target enrollment:** 66 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05471856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05471856, "A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05471856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*